# Emergent Biodefense Operations Lansing LLC

Canonical: https://abierto.us/vendors/emergent-biodefense-operations-lansing-llc-jllwgqx6lna5

- UEI: JLLWGQX6LNA5
- CAGE: 81CF1
- Location: Canton, MA
- Awards in window: 1 (3 transactions), $19,464,480 obligated, September 5, 2025 to July 8, 2026

## Awarding agencies

- Office of Assistant Secretary for Preparedness and Response: 1 awards, $19,464,480

## Industries

- 541714 Research and Development in Biotechnology (except Nanobiotechnology): $19,464,480

## Competition

- Not Competed: 1 awards

## Largest awards

- 75A50122C00047 (definitive contract): $19,464,480, Barda - Aspr / Daappo / Barda DCMA. The Purpose of This Modification Is to Exercise Clin0004b in the Amount of $17,104,200 for 40,000 Treatment Courses of Oral Suspension Tembexa and Updated Article B.2.2 Options, Table 5.. https://www.usaspending.gov/award/CONT_AWD_75A50122C00047_7505_-NONE-_-NONE-/

---
Source: USAspending.gov award data, keyed by UEI. Obligations in the window only. Cite https://abierto.us/vendors/emergent-biodefense-operations-lansing-llc-jllwgqx6lna5.